SCHEMBL2824007

SCHEMBL2824007

COc1ccc(N2CCN(C(=O)C[CH]c3ccccc3)CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.66
MAPT P10636 5/20 0.63
ALDH1A1 P00352 3/20 0.63
LMNA P02545 3/20 0.63
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
HPGD P15428 1/20 0.57
HSD17B10 Q99714 1/20 0.57
GFER P55789 3/20 0.56
TP53 P04637 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3799029 0.90 MAPK1 (0.53) MAPK1MAPTALDH1A1LMNAMEN1
SCHEMBL3798268 0.88 MAPK1 (0.57) MAPK1MAPTALDH1A1LMNAMEN1
SCHEMBL15258825 0.86 HTT (0.57) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL2821852 0.84 GFER (0.53) MAPK1MAPTALDH1A1LMNAMEN1
SCHEMBL3797896 0.84 ME2 (0.64) MAPTALDH1A1LMNAHSD17B10L3MBTL1
SCHEMBL2824681 0.83 MAPT (0.62) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3799763 0.83 GFER (0.62) MAPK1MAPTALDH1A1LMNAHPGD
SCHEMBL3796847 0.82 ME2 (0.53) MAPK1MAPTALDH1A1LMNAMEN1
SCHEMBL3796498 0.81 MAPT (0.58) MAPK1MAPTALDH1A1LMNAMEN1
SCHEMBL20419342 0.81 GFER (0.79) MAPK1MAPTALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901116-B2 Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-12-02 US disclosed
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-03-27 US disclosed
US-8541409-B2 Carbamoyloxy arylalkanoyl arylpiperazine analgesics SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-09-24 US disclosed
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO. LTD. (KR) 2010-06-24 US disclosed
EP-2155736-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK Holdings Co., Ltd. (KR) 2010-02-24 EP disclosed
WO-2008140198-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO., LTD. (KR) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND HTR5A, OPRD1, OPRL1 MAPK1 1564/4885MAPT 3315/4885ALDH1A1 137/4885
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND HTR5A, OPRL1, HDAC3 MAPK1 1614/4885MAPT 2882/4885ALDH1A1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.